David A Proia

Summary

Publications

  1. pmc Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling
    David A Proia
    Synta Pharmaceuticals Corp, Lexington, Massachusetts, United States of America
    PLoS ONE 6:e18552. 2011
  2. pmc Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression
    Suqin He
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Int J Oncol 42:35-43. 2013
  3. pmc Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes
    Julie C Friedland
    Synta Pharmaceuticals Corp, 125 Hartwell Avenue, Lexington, MA, 02421, USA
    Invest New Drugs 32:14-24. 2014
  4. doi request reprint Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib
    Jaime Acquaviva
    Corresponding Author David A Proia, Synta Pharmaceuticals Corp, 125 Hartwell Avenue, Lexington, MA 02421
    Mol Cancer Ther 13:353-63. 2014
  5. pmc Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
    David A Proia
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Invest New Drugs 30:2201-9. 2012
  6. pmc Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer
    Jim Sang
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Cancer Discov 3:430-43. 2013
  7. doi request reprint Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib
    Jaime Acquaviva
    Synta Pharmaceuticals, Corp, Lexington, MA 02421, USA
    Mol Cancer Ther 11:2633-43. 2012
  8. doi request reprint Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy
    Weiwen Ying
    Synta Pharmaceuticals Corp, 45 Hartwell Avenue, Lexington, MA 02421, USA
    Mol Cancer Ther 11:475-84. 2012
  9. ncbi request reprint mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis
    Jaime Acquaviva
    Authors Affiliation Synta Pharmaceuticals Corporation, Lexington, Massachusetts
    Mol Cancer Res 12:703-13. 2014
  10. ncbi request reprint Ganetespib and HSP90: translating preclinical hypotheses into clinical promise
    David A Proia
    Authors Affiliation Synta Pharmaceuticals Corp, Lexington, Massachusetts
    Cancer Res 74:1294-300. 2014

Collaborators

Detail Information

Publications11

  1. pmc Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling
    David A Proia
    Synta Pharmaceuticals Corp, Lexington, Massachusetts, United States of America
    PLoS ONE 6:e18552. 2011
    ..Overall, our findings support Hsp90 inhibition as a novel therapeutic approach for combating diseases dependent on JAK/STAT signaling, with the multimodal action of ganetespib demonstrating advantages over JAK-specific inhibitors...
  2. pmc Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression
    Suqin He
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Int J Oncol 42:35-43. 2013
    ..Together these data suggest that further investigation of ganetespib as a new therapeutic treatment for prostate cancer patients is warranted...
  3. pmc Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes
    Julie C Friedland
    Synta Pharmaceuticals Corp, 125 Hartwell Avenue, Lexington, MA, 02421, USA
    Invest New Drugs 32:14-24. 2014
    ..This preclinical activity profile suggests that ganetespib may offer considerable promise as a new therapeutic candidate for patients with advanced breast cancers. ..
  4. doi request reprint Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib
    Jaime Acquaviva
    Corresponding Author David A Proia, Synta Pharmaceuticals Corp, 125 Hartwell Avenue, Lexington, MA 02421
    Mol Cancer Ther 13:353-63. 2014
    ..Overall these data highlight the potential of ganetespib as a single-agent or combination treatment in BRAF(V600E)-driven melanoma, particularly as a strategy to overcome acquired resistance to selective BRAF inhibitors...
  5. pmc Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
    David A Proia
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Invest New Drugs 30:2201-9. 2012
    ..Taken together, these findings provide preclinical evidence for the use of this combination to treat patients with advanced NSCLC...
  6. pmc Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer
    Jim Sang
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Cancer Discov 3:430-43. 2013
    ..Taken together, these results highlight the therapeutic potential of ganetespib for ALK-driven NSCLC...
  7. doi request reprint Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib
    Jaime Acquaviva
    Synta Pharmaceuticals, Corp, Lexington, MA 02421, USA
    Mol Cancer Ther 11:2633-43. 2012
    ..Taken together, these data underscore the promise of ganetespib as a single-agent or combination treatment in KRAS-driven lung tumors...
  8. doi request reprint Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy
    Weiwen Ying
    Synta Pharmaceuticals Corp, 45 Hartwell Avenue, Lexington, MA 02421, USA
    Mol Cancer Ther 11:475-84. 2012
    ....
  9. ncbi request reprint mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis
    Jaime Acquaviva
    Authors Affiliation Synta Pharmaceuticals Corporation, Lexington, Massachusetts
    Mol Cancer Res 12:703-13. 2014
    ..Moreover, combined therapy regimens with mTOR or dual PI3K/mTOR inhibitors potentiated the antitumor efficacy of ganetespib in multiple in vivo models...
  10. ncbi request reprint Ganetespib and HSP90: translating preclinical hypotheses into clinical promise
    David A Proia
    Authors Affiliation Synta Pharmaceuticals Corp, Lexington, Massachusetts
    Cancer Res 74:1294-300. 2014
    ....
  11. pmc Mitochondrial electron transport is the cellular target of the oncology drug elesclomol
    Ronald K Blackman
    Synta Pharmaceuticals Corp, Lexington, Massachusetts, United States of America
    PLoS ONE 7:e29798. 2012
    ....